You just read:

Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial

News provided by

Asterias Biotherapeutics, Inc.

Nov 08, 2016, 07:00 ET